Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Osiris Finds Problem with Prochymal Trial Design

By Pharmaceutical Processing | March 27, 2009

COLUMBIA, Md. (AP) — Osiris Therapeutics Inc. said Friday it discovered a flaw in a trial of its stem cell candidate Prochymal, and decided to end enrollment of patients early. The trial tested Prochymal as a treatment for Crohn’s disease, a digestive tract disorder. The late stage trial compared the effectiveness of Prochymal against a placebo, and Osiris said the design flaw made the placebo appear more effective. As a result, the company said, Prochymal was unlikely to appear significantly more effective. Osiris stopped enrollment with 210 patients in the trial, out of a planned 270. In premarket trading, Osiris shares plunged $7.40, or 40.4 percent, to $10.90, near their lowest price of the last year. The stock finished at $18.30 Thursday. Prochymal is a formulation of adult stem cells and is Osiris’ lead drug candidate. Osiris is developing the product through a partnership with Genzyme Corp., and is also testing Prochymal as a treatment for graft vs. host disease and type 1 diabetes. Osiris said there were no safety issues with the drug. The company did not immediately return calls seeking comment.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE